表紙
市場調査レポート

世界の動物用寄生虫駆除剤市場動向・予測:病原生物・製品・動物種・地域別

Global Veterinary Paraciticides Market Segmented By Disease Causing Organisms, By Products, By Animal Types & By Geography - Trends & Forecasts 2014- 2019

発行 Mordor Intelligence LLP 商品コード 319397
出版日 ページ情報 英文 56 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
世界の動物用寄生虫駆除剤市場動向・予測:病原生物・製品・動物種・地域別 Global Veterinary Paraciticides Market Segmented By Disease Causing Organisms, By Products, By Animal Types & By Geography - Trends & Forecasts 2014- 2019
出版日: 2016年03月01日 ページ情報: 英文 56 Pages
概要

世界の動物用寄生虫駆除剤市場は2014年から2020年の間に6.0%のCAGRで拡大し、市場額は2014年の289億米ドルから2020年までに397億米ドルに達すると予測されています。

当レポートでは、世界の動物用寄生虫駆除剤市場について、病原生物、製品、動物種および地域別に調査分析し、市場の現況と将来の予測、包括的な競合情勢の分析、および主要企業の市場シェアや近年の発展動向を含む詳細情報などを提供しています。

第1章 イントロダクション

第2章 市場分析

  • 市販の動物薬
  • 獣医学vs.人間の医学

第3章 市場力学

  • 市場促進因子
  • 市場抑制因子
  • ポーターのファイブフォース分析

第4章 世界の動物用寄生虫駆除剤市場区分

  • 世界の動物用寄生虫駆除剤市場:病原生物別
    • イントロダクション
    • 外部寄生虫駆除剤
      • ノミ
      • シラミ
      • ダニ
    • 内部寄生虫駆除剤
      • 胃腸管線虫
      • 犬糸状虫
      • 肺線虫
  • 世界の動物用寄生虫駆除剤市場:製品別
    • 経口液体
    • タブレット
    • 注射剤
    • スプレー
    • プアオン
    • スポットオン(滴下)
    • カラ―
    • イヤータグ
  • 世界の動物用寄生虫駆除剤市場:種類別
    • コンパニオンアニマル
      • イヌ
      • ネコ
    • 家畜
  • 世界の動物用寄生虫駆除剤市場:地域別
    • 北米
    • 欧州
    • アジア太平洋

第5章 競合情勢

  • 市場の主要企業
  • M&A
  • 新製品発売
  • 合意、協力および提携

第6章 企業プロファイル

  • Zoetis animal healthcare
    • 財務概要
    • 事業概要
    • 事業戦略
  • Merck
  • Merial (Sanofiの動物保健部門)
  • Elanco
  • Bayer healthcare
  • Novartis Animal Health, Inc.
  • Virbac
  • Boehringer Ingelheim

第7章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

The global market for paraciticides in veterinary healthcare is estimated to be worth $2.89 billion in 2014. Expected to grow at a CAGR of 6.0%, the market is set to reach US$ 3.97 billion by 2019.

Veterinary pharmaceuticals, including parasiticides, have transformed the health of companion and livestock animals across the globe over the past two decades. Today, the spectrum of parasiticides for veterinary applications continues to expand with a variety of ectoparasiticides, endoparasiticides, and endectocides being launched every year. Constant innovationis leading to the emergence of novel parasiticide delivery systems as well.

However, stringent regulations and norms are the major constraints for market growth, with some countries not allowing the use of paraciticides on food-producing animals.

This report provides an extensive coverage of the market: By disease-causing organisms - Ectoparaciticides (Fleas, Lice, Mice) and Endoparaciticides (Gastrointestinal, nematode, heartworms,Lungworms); By species within companion and farm animals;By geography - North America, Asia-Pacific, Europe and the rest of world.

A majority of the growth in the market is expected to be from the emerging markets in the Asia-Pacific and Latin American regions.

Pfizer (U.S.), Merck (U.S.), Sanofi-Aventis (France), Bayer HealthCare (Germany), Virbac (France), Novartis (Switzerland), Boehringer Ingelheim (Germany), Heska Corporation (U.S.), Bioniche Animal Health Canada, Inc. (Canada), and Ceva (France) are the key players in the global animal anti-infectives market.

What makes our report unique

  • 1) In-depth analysis of current market trends and future forecasts of the market based on different paraciticides available for animal healthcare.
  • 2) We provide the longest possible market segmentation based on paraciticide type, animal species and by geography.
  • 3) The comprehensive competitive landscape section in the report provides information about major players in the market, their market shares and recent developments.

Table of Contents

1. INTRODUCTION

  • 1.1. Market Definition
  • 1.2. Market Recent Trend

2. Market Analysis

  • 2.1. Market Animal Health Products
  • 2.2. Animal medicines vs human Medicines

3. Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Increase in pet ownership
    • 3.1.2. Improved Nutrition
    • 3.1.3. Intensifying consumer focus on food safety
    • 3.1.4. Greater Livestock production
    • 3.1.5. Increasing Zoonotic and Foodborne Diseases
  • 3.2. Market Constraints
    • 3.2.1. Scarcity of arable land and water
    • 3.2.2. Increased competition for cultivated land
    • 3.3.3. Cost effective production
  • 3.3. Porter's Five Force Analysis
    • 3.3.1. Threat of New Entrant
    • 3.3.2. Internal Rivalry
    • 3.3.3. Buyer bargaining power
    • 3.3.4. Supplier bargaining power
    • 3.3.5. Threat of substitutes

4.Global veterinary paraciticides market Segmentation

  • 4.1. Global veterinary Parasiticides Market, By disease causing organisms
    • 4.1.1. Introduction
    • 4.1.2. Ectoparaciticides
      • 4.1.2.1. Fleas
      • 4.1.2.1. Lice
      • 4.1.2.1. Mites
    • 4.1.3. Endoparaciticides
      • 4.1.3.1. Gastrointestinal nematode
      • 4.1.3.2. Heartworms
      • 4.1.3.3. Lungworms
  • 4.2. Global veterinary Parasiticides Market, By products
    • 4.2.1. Oral Liquids
    • 4.2.2. Tablets
    • 4.2.3. Injectables
    • 4.2.4. Sprays
    • 4.2.5. Pour On
    • 4.2.6. Spot On
    • 4.2.7. Collars
    • 4.2.8. Ear Tags
  • 4.3. Global veterinary Parasiticides Market, By species
    • 4.3.1. Companion Animals
      • 4.3.1.1. Dogs
      • 4.3.1.2. Cats
      • 4.3.1.3. Horses
    • 4.3.2. Farm animal
      • 4.3.2.1. Cattle
      • 4.3.2.2. Swine
      • 4.3.2.3. Poultry
      • 4.3.2.4. Fish
      • 4.3.2.5. Sheep
  • 4.4. .Global veterinary Market Segmentation, By Geography
    • 4.4.1. North America
      • 4.4.1.1. US
      • 4.4.1.2. Mexico
      • 4.4.1.3. Canada
    • 4.4.2. Europe
      • 4.4.2.1. France
      • 4.4.2.2. Italy
      • 4.4.2.3. Germany
      • 4.4.2.4. Spain
      • 4.4.2.5. Sweden
      • 4.4.2.6. Rest of Europe
    • 4.4.3. Asia-Pacific
      • 4.4.3.1. India
      • 4.4.3.2. China
      • 4.4.3.3. Japan
      • 4.4.3.4. Rest of Asia-Pacific

5. Competitive landscape

  • 5.1. Major players in the market
  • 5.2. Mergers and acquisitions
  • 5.3. New product launches
  • 5.4. Agreement, Collaborations and Partnerships

6. Company profiles

  • 6.1. Zoetis animal healthcare
    • 6.1.1. Financial Overview
    • 6.1.2. Business overview
    • 6.1.3. Business strategies
  • 6.2. Merck
    • 6.2.1. Financial Overview
    • 6.2.2. Business overview
    • 6.2.3. Business strategies
  • 6.3. Merial (Animal Health Division Of Sanofi)
    • 6.3.1. Financial Overview
    • 6.3.2. Business overview
    • 6.3.3. Business strategies
  • 6.4. Elanco
    • 6.4.1. Financial Overview
    • 6.4.2. Business overview
    • 6.4.3. Business strategies
  • 6.5. Bayer healthcare
    • 6.5.1. Financial Overview
    • 6.5.2. Business overview
    • 6.5.3. Business strategies
  • 6.6. Novartis Animal Health, Inc.
    • 6.6.1. Financial Overview
    • 6.6.2. Business overview
    • 6.6.3. Business strategies
  • 6.7. Virbac
    • 6.7.1. Financial Overview
    • 6.7.2. Business overview
    • 6.7.3. Business strategies
  • 6.8. Boehringer Ingelheim
    • 6.8.1. Financial Overview
    • 6.8.2. Business overview
    • 6.8.3. Business strategies

7. Appendix

  • 7.1.Abbreviations
  • 7.2.Sources
  • 7.3.Bibliography
  • 7.4.Disclaimer
Back to Top